Address2130 W Holcombe Blvd
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res. 2019 11 01; 25(21):6429-6442. PMID: 31439581; PMCID: PMC6825560.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    2. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma. Cancer Res. 2014 Dec 01; 74(23):7037-47. PMID: 25297634; PMCID: PMC4347853.
      Citations: 94     Fields:    Translation:HumansCells
    3. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014 Nov 01; 20(21):5537-46. PMID: 24803579; PMCID: PMC4216765.
      Citations: 70     Fields:    Translation:HumansCells
    4. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67. PMID: 23251002; PMCID: PMC3563727.
      Citations: 134     Fields:    Translation:HumansAnimalsCells
    5. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 2012 Mar; 25(2):248-58. PMID: 22171948.
      Citations: 58     Fields:    Translation:HumansCells
    6. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010 Nov 01; 70(21):8736-47. PMID: 20959481; PMCID: PMC4286702.
      Citations: 140     Fields:    Translation:HumansCells
    7. Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, Davies MA, Murph MM. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer. 2010 Jun 09; 9:140. PMID: 20529378; PMCID: PMC2895597.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    8. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009 Aug; 8(8):2079-85. PMID: 19671763; PMCID: PMC3346953.
      Citations: 68     Fields:    Translation:HumansCells
    9. Gopal YN, Chanchorn E, Van Dyke MW. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther. 2009 Mar; 8(3):552-62. PMID: 19276167.
      Citations: 34     Fields:    Translation:HumansCells
    10. Gopal YN, Arora TS, Van Dyke MW. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem Biol. 2007 Jul; 14(7):813-23. PMID: 17656318.
      Citations: 51     Fields:    Translation:HumansCells
    11. Baby J, Pickering BF, Vashisht Gopal YN, Van Dyke MW. Constitutive and inducible nuclear factor-kappaB in immortalized normal human bronchial epithelial and non-small cell lung cancer cell lines. Cancer Lett. 2007 Sep 18; 255(1):85-94. PMID: 17493745.
      Citations: 12     Fields:    Translation:HumansCells
    12. Gopal YN, Van Dyke MW. Depletion of histone deacetylase protein: a common consequence of inflammatory cytokine signaling? Cell Cycle. 2006 Dec; 5(23):2738-43. PMID: 17172847.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    13. Vashisht Gopal YN, Arora TS, Van Dyke MW. Tumour necrosis factor-alpha depletes histone deacetylase 1 protein through IKK2. EMBO Rep. 2006 Mar; 7(3):291-6. PMID: 16374504; PMCID: PMC1456891.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    14. Vashisht Gopal YN, Van Dyke MW. Combinatorial determination of sequence specificity for nanomolar DNA-binding hairpin polyamides. Biochemistry. 2003 Jun 10; 42(22):6891-903. PMID: 12779344.
      Citations: 7     Fields:    Translation:Cells
    15. Vashisht Gopal YN, Konuru N, Kondapi AK. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)]. Arch Biochem Biophys. 2002 May 01; 401(1):53-62. PMID: 12054487.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    16. Vashisht Gopal YN, Kondapi AK. Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium. J Biosci. 2001 Jun; 26(2):271-6. PMID: 11426063.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    17. Vashisht Gopal YN, Jayaraju D, Kondapi AK. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene. Arch Biochem Biophys. 2000 Apr 01; 376(1):229-35. PMID: 10729210.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    18. Jayaraju D, Gopal YN, Kondapi AK. Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex. Arch Biochem Biophys. 1999 Sep 01; 369(1):68-77. PMID: 10462441.
      Citations: 3     Fields:    Translation:AnimalsCells
    19. Gopal YN, Jayaraju D, Kondapi AK. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action. Biochemistry. 1999 Apr 06; 38(14):4382-8. PMID: 10194357.
      Citations: 10     Fields:    Translation:AnimalsCells
    20. RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. Oncotarget. 7:36711-36718.
    21. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clinical Cancer Research. 15:7538-7546.
    YENNU NANDA's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (170)
    Co-Authors (18)
    Similar People (60)
    Same Department Expand Description